Vir Biotechnology (VIR) Change in Accured Expenses (2018 - 2026)

Vir Biotechnology has reported Change in Accured Expenses for 9 years, with the latest figure at -$17.2 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 195.62% year-over-year to -$17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.7 million (down 179.6% YoY) and the FY2025 annual result came in at -$9.5 million, up 85.15% from the prior year.
• Change in Accured Expenses retreated to -$17.2 million in Q1 2026 per VIR's latest filing, from $10.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $433.6 million in Q1 2022 and troughed at -$288.2 million in Q2 2022.
• A 5-year average of -$27.4 million and a median of -$23.5 million in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 2402.84% in 2022, down 8228.76% in 2022.
• Over 5 years, Change in Accured Expenses stood at -$80.7 million in 2022, then soared by 48.02% to -$41.9 million in 2023, then slipped by 15.65% to -$48.5 million in 2024, then surged by 120.84% to $10.1 million in 2025, then slumped by 270.46% to -$17.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$17.2 million, $10.1 million, and -$14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.